Literature DB >> 30769264

Electronic cigarette and tobacco use in individuals entering methadone or buprenorphine treatment.

Stephen R Baldassarri1, David A Fiellin2, Mary Ellen Savage3, Lynn M Madden4, Mark Beitel3, Lara K Dhingra5, Lisa Fucito6, Deepa Camenga7, Pooja Bollampally8, Declan T Barry9.   

Abstract

BACKGROUND: Although smoking is prevalent among populations with opioid use disorder (OUD), few studies have examined electronic cigarette (EC) use in individuals seeking opioid agonist therapy (OAT). The aim of this study was to evaluate the prevalence and correlates of EC use among individuals seeking OAT.
METHODS: 782 patients seeking OAT for OUD completed surveys assessing current and past EC use, reasons for use, current and past cigarette smoking, nicotine dependence, psychiatric distress, trauma, and pain. Bivariate and multivariate models evaluated correlates of daily EC use, past-30-day EC use, and current cigarette smoking.
RESULTS: 6% of patients reported daily EC use, 18% reported past-30-day use, 62% reported EC use history, and 85% reported current cigarette smoking. 46% reported using ECs to quit or cut down smoking. In multivariate analyses, daily EC use was associated with higher odds of being a former smoker (OR 21; CI 1.7-273) and lower odds of ever smoking more than 100 cigarettes (OR 0.07; CI 0.01-0.32), while EC use in the past 30 days was associated with lower odds of being Caucasian (OR 0.55; CI 0.34-0.89), ever smoking more than 100 cigarettes (OR 0.13; CI 0.02-0.67), and history of chronic pain (OR 0.59; CI 0.38-0.90), and higher odds of reporting psychiatric distress (OR 1.5; CI 1.1-2.2).
CONCLUSIONS: EC use is common among people with OUD who smoke cigarettes. Those with daily use had higher odds of being former smokers than current smokers. Interventions using ECs may be effective to help reduce harms and mortality in OUD.
Copyright © 2019. Published by Elsevier B.V.

Entities:  

Keywords:  Electronic cigarette; Methadone; Nicotine; Opioid; Smoking; Tobacco

Mesh:

Substances:

Year:  2019        PMID: 30769264      PMCID: PMC6637405          DOI: 10.1016/j.drugalcdep.2018.12.012

Source DB:  PubMed          Journal:  Drug Alcohol Depend        ISSN: 0376-8716            Impact factor:   4.492


  22 in total

1.  The Fagerström test for nicotine dependence: a comparison of standard scoring and latent class analysis approaches.

Authors:  Carla L Storr; Beth A Reboussin; James C Anthony
Journal:  Drug Alcohol Depend       Date:  2005-11-01       Impact factor: 4.492

2.  Counseling plus buprenorphine-naloxone maintenance therapy for opioid dependence.

Authors:  David A Fiellin; Michael V Pantalon; Marek C Chawarski; Brent A Moore; Lynn E Sullivan; Patrick G O'Connor; Richard S Schottenfeld
Journal:  N Engl J Med       Date:  2006-07-27       Impact factor: 91.245

3.  Origin and use of the 100 cigarette criterion in tobacco surveys.

Authors:  S J Bondy; J C Victor; L M Diemert
Journal:  Tob Control       Date:  2009-06-01       Impact factor: 7.552

Review 4.  Cigarette smoking in methadone maintained patients: an up-to-date review.

Authors:  Ali Zirakzadeh; Charles Shuman; Erinn Stauter; J Taylor Hays; Jon O Ebbert
Journal:  Curr Drug Abuse Rev       Date:  2013-03

5.  Smoking cessation services in U.S. methadone maintenance facilities.

Authors:  Kimber P Richter; Won S Choi; Robert M McCool; Kari J Harris; Jasjit S Ahluwalia
Journal:  Psychiatr Serv       Date:  2004-11       Impact factor: 3.084

6.  A 33-year follow-up of narcotics addicts.

Authors:  Y I Hser; V Hoffman; C E Grella; M D Anglin
Journal:  Arch Gen Psychiatry       Date:  2001-05

7.  The Fagerström Test for Nicotine Dependence: a revision of the Fagerström Tolerance Questionnaire.

Authors:  T F Heatherton; L T Kozlowski; R C Frecker; K O Fagerström
Journal:  Br J Addict       Date:  1991-09

8.  Pain as a motivator of smoking: effects of pain induction on smoking urge and behavior.

Authors:  Joseph W Ditre; Thomas H Brandon
Journal:  J Abnorm Psychol       Date:  2008-05

9.  Psychometric properties of the BASIS-24© (Behaviour and Symptom Identification Scale-Revised) Mental Health Outcome Measure.

Authors:  I M Cameron; L Cunningham; J R Crawford; J M Eagles; S V Eisen; K Lawton; S A Naji; R J Hamilton
Journal:  Int J Psychiatry Clin Pract       Date:  2007       Impact factor: 1.812

10.  Cigarette smoking and interest in quitting in methadone maintenance patients.

Authors:  Shadi Nahvi; Kimber Richter; Xuan Li; Laxmi Modali; Julia Arnsten
Journal:  Addict Behav       Date:  2006-02-13       Impact factor: 3.913

View more
  5 in total

1.  Correlates of sleep quality and excessive daytime sleepiness in people with opioid use disorder receiving methadone treatment.

Authors:  Stephen R Baldassarri; Mark Beitel; Andrey Zinchuk; Nancy S Redeker; David E Oberleitner; Lindsay M S Oberleitner; Danilo Carrasco; Lynn M Madden; Nathan Lipkind; David A Fiellin; Lori A Bastian; Kevin Chen; H Klar Yaggi; Declan T Barry
Journal:  Sleep Breath       Date:  2020-06-17       Impact factor: 2.816

Review 2.  Achieving Smoking Cessation Among Persons with Opioid Use Disorder.

Authors:  Cynthia Vlad; Julia H Arnsten; Shadi Nahvi
Journal:  CNS Drugs       Date:  2020-04       Impact factor: 5.749

3.  Transport of Maternally Administered Pharmaceutical Agents Across the Placental Barrier In Vitro.

Authors:  Rajeendra L Pemathilaka; Nima Alimoradi; David E Reynolds; Nicole N Hashemi
Journal:  ACS Appl Bio Mater       Date:  2022-04-05

4.  Interest in Electronic Cigarettes for Smoking Cessation Among Adults With Opioid Use Disorder in Buprenorphine Treatment: A Mixed-Methods Investigation.

Authors:  Joanna M Streck; Susan Regan; Jordan Neil; Sara Kalkhoran; Priya S Gupta; Benjamin Bearnot; Faith K Coker; Kelly M Kalagher; Elyse R Park; Sarah Wakeman; Nancy A Rigotti
Journal:  Nicotine Tob Res       Date:  2022-06-15       Impact factor: 5.825

5.  Effect of brief nicotine corrective messaging on nicotine beliefs in persons who use opioids.

Authors:  Maria A Parker; Jodi E Byers; Andrea C Villanti
Journal:  Exp Clin Psychopharmacol       Date:  2021-07-22       Impact factor: 3.157

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.